Psychedelic Institute - Psychedelics in Mental Health
Psychedelic Institute - Psychedelics in Mental Health
Ketamine Psychedelic Preparation, Integration, Coaching
⌘K
Contact
Psychedelic Institute - Psychedelics in Mental Health
psychedelic cognitive behavioral therapy

Spotlight: Key competencies for psychedelic treatment in real-world mental health care settings (Wolff, et al, 2025)

"To accommodate mainstream adoption of these treatments, the competencies framework we present respects the distinctive contextual and cultural sensitivities of psychedelic care while remaining anchored in established psychotherapeutic, medical, and scientific paradigms."
Michael DeMarco, PhD

by Michael DeMarco, PhD

(2025):"Designed for varied service models, the framework is substance-unspecific (i.e., covering various classical and atypical psychedelic agents) and transtheoretical (i.e., compatible with cognitive-behavioral, psychodynamic, humanistic-experiential, systemic and other psychotherapeutic orientations)."

More like this

Spotlight: N,N-dimethyltryptamine elicits antidepressant and anxiolytic effects in helpless mice: a comparative study with S-ketamine (da Sousa-Silva, et al, 2026)

DMT compared with ketamine variant, esketamine in mice.
Spotlight: "A Blueprint for Implementing Ketamine-Assisted Psychotherapy in Palliative Care: Design, Process, and Treatment Patterns of a Real-World Clinical Program" (Horowitz, et al, 2026)

Spotlight: "A Blueprint for Implementing Ketamine-Assisted Psychotherapy in Palliative Care: Design, Process, and Treatment Patterns of a Real-World Clinical Program" (Horowitz, et al, 2026)

"To our knowledge, this is the largest published cohort of KAP in an academic palliative care context. Our Pal-KAP experience suggests that KAP can be delivered safely and ethically, providing a practical blueprint for programs exploring innovative ways to address Psychospiritual distress (PSD)"

Moderating factors in psilocybin-assisted treatment affecting mood and personality: A naturalistic, open-label investigation (Irrmischer, et al, 2025)

"Findings indicate that individual psilocybin-assisted therapy has the potential for beneficial effects on mood and personality characteristics. Moreover, the study highlights the importance of subjective experiences and demographic factors in moderating this effect."

Intravenous ketamine versus esketamine for depression: a systematic review and meta-analysis (Elmosalamy, et al, 2025)

"Based on the currently available comparative evidence, which is almost entirely observational, IV ketamine and IN esketamine show comparable acute response and remission rates, though IV ketamine may act faster."

The Role of Psychedelics in the Treatment of Substance Use Disorders: An Overview of Systematic Reviews (Correa de Costa, et al, 2025)

"...evidence suggests that the use of serotonergic and non-serotonergic psychedelics (ketamine) for the treatment of SUD may provide advantages over traditional therapeutics, and these compounds may eventually become part of the next generation of treatments for SUD under specific circumstances."

Spotlight: A long, strange trip: Ketamine treatment in psychiatry (Nutt, et al, 2025)

"...mystical experiences were strongly related to immediate and sustained psychiatric benefits at the group level and on an individual, session-by-session basis across the six doses, providing mechanistic support for ketamine-psychotherapy pairings."
Mastodon Mastodon